Scholar Rock Stock Forecast, Price & News

+0.35 (+1.76%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
243,343 shs
Average Volume
180,410 shs
Market Capitalization
$710.23 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Scholar Rock logo

About Scholar Rock

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.


Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week Low at $19.96
January 13, 2022 |
Scholar Rock (NASDAQ:SRRK) Hits New 1-Year Low at $21.51
January 7, 2022 |
Scholar Rock (NASDAQ:SRRK) Shares Gap Down to $25.42
December 28, 2021 |
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$15.40 million
Book Value
$7.64 per share


Net Income
$-86.48 million
Net Margins
Pretax Margin




Free Float
Market Cap
$710.23 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.33 out of 5 stars

Medical Sector

243rd out of 1,405 stocks

Biological Products, Except Diagnostic Industry

42nd out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

Is Scholar Rock a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock
or view top-rated stocks.

How has Scholar Rock's stock been impacted by COVID-19?

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SRRK stock has increased by 36.1% and is now trading at $20.23.
View which stocks have been most impacted by COVID-19

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Scholar Rock

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its quarterly earnings results on Monday, November, 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.17. The business earned $5.46 million during the quarter, compared to analysts' expectations of $4.65 million. Scholar Rock had a negative net margin of 672.72% and a negative trailing twelve-month return on equity of 54.11%. The company's revenue was up 79.9% on a year-over-year basis. During the same period last year, the firm posted ($0.79) EPS.
View Scholar Rock's earnings history

What price target have analysts set for SRRK?

4 brokers have issued 1-year target prices for Scholar Rock's stock. Their forecasts range from $28.00 to $79.00. On average, they anticipate Scholar Rock's stock price to reach $57.25 in the next year. This suggests a possible upside of 183.0% from the stock's current price.
View analysts' price targets for Scholar Rock
or view top-rated stocks among Wall Street analysts.

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:
  • Nagesh K. Mahanthappa, President, Chief Executive Officer & Director
  • Edward H. Myles, Chief Financial Officer & Head-Business Operations (LinkedIn Profile)
  • Gregory J. Carven, Chief Scientific Officer
  • Yung H. Chyung, Chief Medical Officer
  • George G Nomikos, SVP-Medical & Clinical Science

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $20.23.

How much money does Scholar Rock make?

Scholar Rock has a market capitalization of $710.23 million and generates $15.40 million in revenue each year. The company earns $-86.48 million in net income (profit) each year or ($3.41) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 119 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is

Where are Scholar Rock's headquarters?

Scholar Rock is headquartered at 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3860, via email at [email protected], or via fax at 866-493-4935.

This page was last updated on 1/17/2022 by Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.